DrugBiological
Adalimumab clinical trials
Also written Humira, MSB11022 and BCD-057.
Includes 10 studies of BI 695501, 6 studies of ABP 501 and 4 studies of PF-06410293.
How each study uses Adalimumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Adalimumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 31 Dec 2002 · HUMIRA · BLA 125057 (FDA, Drugs@FDA)
- European Union
- 1 Sept 2003 · Trudexa · EMEA/H/C/000482 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
317 studies that test it; most in 2006 (21)
| Year | Studies |
|---|---|
| 2000 | 4 |
| 2002 | 6 |
| 2003 | 14 |
| 2004 | 10 |
| 2005 | 9 |
| 2006 | 21 |
| 2007 | 18 |
| 2008 | 13 |
| 2009 | 15 |
| 2010 | 17 |
| 2011 | 12 |
| 2012 | 15 |
| 2013 | 17 |
| 2014 | 20 |
| 2015 | 19 |
| 2016 | 18 |
| 2017 | 9 |
| 2018 | 3 |
| 2019 | 13 |
| 2020 | 8 |
| 2021 | 7 |
| 2022 | 11 |
| 2023 | 7 |
| 2024 | 10 |
| 2025 | 7 |
| 2026 | 14 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 176 · Other 143
Abbott (61) · AbbVie (27) · AbbVie (prior sponsor, Abbott) (26) · Boehringer Ingelheim (10) · Assistance Publique - Hôpitaux de Paris (7) · Amgen (6) · Alvotech Swiss AG (6) · Innovaderm Research Inc. (5)
Often tested with
Tested in the same studies.
Methotrexate (26) · Infliximab (18) · Etanercept (17) · Certolizumab Pegol (9) · Secukinumab (7) · Tocilizumab (7) · Abatacept (7) · Azathioprine (6)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 5 phase 3 studies under way
Adalimumab is the comparator. A study of two new drugs counts under both.
- 1Ixekizumab · Eli Lilly and Company
- 1Netakimab · Biocad
- 1Baricitinib · Eli Lilly and Company
- 1Bimekizumab · University Hospital, Rouen · next primary completion Apr 2030
Reaching primary completion within a year · 14, 1 in phase 3
Studies that test Adalimumab, phase 3 first.
- Jun 2027Treatment FOr Corticosteroid Dependent UveitiSPhase 3 · Assistance Publique - Hôpitaux de Paris
- Nov 2026"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"Phase 2 · Assistance Publique - Hôpitaux de Paris
- Nov 2026A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the ColonPhase 1 · Surmount Services, Inc.
- Dec 2026Apremilast and Adalimumab in Psoriatic Arthritis PatientsNot applicable · Tanta University
- Jan 2027Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VIPhase 1/2 · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Jan 2027An Early Feasibility Study of the BioJet™ Oral Biotherapeutic Delivery System for Administration of Therapeutic Agents in Healthy ParticipantsPhase 1 · Biora Therapeutics, Inc.
- Jun 2027To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy SubjectsPhase 1 · Prestige Biopharma Limited
- Jun 2027Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitisPhase 2 · ANRS, Emerging Infectious Diseases
- Jun 2027Subconjunctival Humira for Boston KeratoprosthesisPhase 1 · Massachusetts Eye and Ear Infirmary
- Jun 2027Baricitinib in the Treatment of Intestinal Behçet's SyndromePhase 2 · Peking Union Medical College Hospital
Studies
Open first, then newest update. How each study uses Adalimumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 319
- Withdrawal Versus Continued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile Idiopathic ArthritisNot yet recruitingPhase 4Oslo University HospitalNCT07904780Written as Adalimumab
- An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)RecruitingPhase 2Yale UniversityNCT06996652Written as Adalimumab
- A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the ColonRecruitingPhase 1Surmount Services, Inc.NCT07788807Written as Adalimumab
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 DiabetesRecruitingPhase 1/2City of Hope Medical CenterNCT07061574Written as Adalimumab
- An Early Feasibility Study of the BioJet™ Oral Biotherapeutic Delivery System for Administration of Therapeutic Agents in Healthy ParticipantsNot yet recruitingPhase 1Biora Therapeutics, Inc.NCT07849153Written as Hadlima®
- Baricitinib in the Treatment of Intestinal Behçet's SyndromeRecruitingPhase 2Peking Union Medical College HospitalNCT06849908Written as Adalimumab
- A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 4Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07564505Written as Adalimumab Solution for Injection
- Apremilast and Adalimumab in Psoriatic Arthritis PatientsNot yet recruitingNot applicableTanta UniversityNCT07398651Written as Adalimumab
- Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing PolychondritisRecruitingPhase 2University of PennsylvaniaNCT06941376Written as Adalimumab
- A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabRecruitingPhase 3AbbVieNCT06100744Written as Adalimumab
- Subconjunctival Humira for Boston KeratoprosthesisNot yet recruitingPhase 1Massachusetts Eye and Ear InfirmaryNCT06926478Written as Adalimumab Injection
- Adalimumab Dose Adjustment for Pediatric Uveitis Treatment TrialNot yet recruitingPhase 4Nisha AcharyaNCT07699107Written as Adalimumab/Biosimilar
- Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic UveitisNot yet recruitingPhase 4Centre Hospitalier Universitaire de Saint EtienneNCT06390436Written as Adalimumab Injection
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Adalimumab
- Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseRecruitingPhase 3University of NebraskaNCT03414502Written as Adalimumab
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Adalimumab
- Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.RecruitingPhase 4Centre Hospitalier Universitaire de Saint EtienneNCT06180382Written as Adalimumab
- A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque PsoriasisNot yet recruitingPhase 4Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07529925Written as Adalimumab Solution for Injection
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained RemissionRecruitingNot applicableMarmara UniversityNCT07491913Written as Adalimumab
- Preventing Structural Damage in Early Psoriatic ArthritisRecruitingPhase 4Chinese University of Hong KongNCT07486843Written as Amgevita 40Mg Solution for Injection
See all 319 studies that test Adalimumab →
Given beside what is tested · 33 — Adalimumab is usual care or a partner of the new treatment
- TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal ResponseRecruitingPhase 4Sixth Affiliated Hospital, Sun Yat-sen UniversityNCT07510191Written as Standard-Dose Adalimumab
- A Study of LAD191 in Adults With Hidradenitis SuppurativaRecruitingPhase 2Almirall, S.A.NCT07151937Written as Adalimumab
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory ArthritisRecruitingPhase 2Tom AppletonNCT06037811Written as Adalimumab
- Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug MonitoringRecruitingPhase 4Reade Rheumatology Research InstituteNCT04194827Written as Adalimumab
- A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating AdalimumabRecruitingPhase 4Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesNCT04183608Written as Adalimumab
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's DiseaseActive, not recruitingPhase 4TakedaNCT06045754Written as Adalimumab
- Using a Contact Dermatitis Model With Biologic Medications to Study Skin InflammationActive, not recruitingPhase 2/3Wei-Che KoNCT05535738Written as Adalimumab
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedPhase 3UCB Biopharma SRLNCT03412747Written as Adalimumab
- Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)CompletedPhase 4University Hospital, ToursNCT01895764Written as Adalimumab
- Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED TrialCompletedPhase 4University of OxfordNCT03739853Written as Adalimumab
- A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's DiseaseWithdrawnPhase 2Janssen Research & Development, LLCNCT04655807Written as Adalimumab
- Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and TaiwanCompletedPhase 4Keio UniversityNCT03505008Written as Adalimumab
- A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to MethotrexateActive, not recruitingPhase 3Bristol-Myers SquibbNCT04909801Written as Adalimumab
- A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)CompletedPhase 4Astellas Pharma Korea, Inc.NCT03737708Written as adalimumab
- Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease ActivityCompletedPhase 4Reade Rheumatology Research InstituteNCT04222920Written as Adalimumab
- Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedPhase 4Samsung Bioepis Co., Ltd.NCT05510063Written as Humira (Adalimumab)
- Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)TerminatedNot applicableNantes University HospitalNCT02878083Written as ADALIMUMAB
- A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive MelanomasCompletedPhase 1Hoffmann-La RocheNCT04551352Written as Adalimumab
- Hidradenitis Suppurativa Patient Experience With Humira TreatmentWithdrawnPhase 4Wake Forest University Health SciencesNCT04132388Written as Adalimumab
- Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)CompletedPhase 2Applied Molecular TransportNCT05372939Written as Humira (adalimumab)
Showing 20 of 33.
As the comparator · 73 — what is tested is compared with Adalimumab
- Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of BimekizumabNot yet recruitingPhase 3University Hospital, RouenNCT07836283Written as adalimumab
- Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARDRecruitingPhase 2Changchun GeneScience Pharmaceutical Co., Ltd.NCT07423533Written as adalimumab injection 40 mg
- The Efficacy and Safety of Deucravacitinib in Takayasu's ArteritisNot yet recruitingPhase 4Chinese SLE Treatment And Research GroupNCT07013838Written as Adalimumab
- Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)RecruitingPhase 4Universita di VeronaNCT06527534Written as Adalimumab
- Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid ArthritisNot yet recruitingPhase 4Leiden University Medical CenterNCT05502731Written as Adalimumab
- A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisCompletedPhase 3UCB Biopharma SRLNCT03895203Written as Adalimumab
- Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic ArthritisCompletedPhase 2MoonLake Immunotherapeutics AGNCT05640245Written as Adalimumab
- Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaCompletedPhase 2MoonLake Immunotherapeutics AGNCT05322473Written as Adalimumab
- A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisActive, not recruitingPhase 3Eli Lilly and CompanyNCT04527380Written as Adalimumab
- An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's DiseaseTerminatedPhase 2/3AstraZenecaNCT03759288Written as Humira®
- Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque PsoriasisActive, not recruitingPhase 3BiocadNCT06640517Written as Adalimumab
- A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive UveitisActive, not recruitingPhase 3Eli Lilly and CompanyNCT04088409Written as Adalimumab
- A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting ConditionsCompletedPhase 1Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.NCT07147257Written as HUMIRA®
- A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)CompletedPhase 3AbbVieNCT03104400Written as Adalimumab
- Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory UveitisCompletedPhase 2Assistance Publique - Hôpitaux de ParisNCT02929251Written as Adalimumab
- Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque PsoriasisCompletedPhase 3Shanghai Henlius BiotechNCT03316781Written as adalimumab
- Safety and Efficacy of Adalimumab Versus Ustekinumab for One YearCompletedPhase 3Janssen Scientific Affairs, LLCNCT03464136Written as Adalimumab (40 mg)
- A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)Active, not recruitingPhase 2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT06242652Written as Adalimumab
- Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)Active, not recruitingPhase 3BiocadNCT06333210Written as Adalimumab subcutaneous injection
- A Clinical Study With Adalimumab BiosimilarCompletedPhase 1Laboratorios Richmond S.A.C.I.F.NCT06291948Written as Humira® (adalimumab) AC Pen [Reference Product]
Showing 20 of 73.
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting1
Stopped1
- Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious UveitisTerminatedNov 2, 2026NCT02706704
Newly registered1
Codes
What other systems call Adalimumab · ClinicalTrials.gg INT006554
- MeSH (NLM) D000068879AdalimumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) FYS6T7F842ADALIMUMABConfirmed FDA, NLM, Wikidata
- RxNorm 327361Confirmed FDA, Wikidata
- Wikidata Q348260adalimumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65216AdalimumabOne source FDA
- DrugBank DB00051One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068879 | Adalimumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | FYS6T7F842 | ADALIMUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 327361 | — | Confirmed FDA, Wikidata |
| Wikidata | Q348260 | adalimumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65216 | Adalimumab | One source FDA |
| DrugBank | DB00051 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.